Drug Profile
Research programme: fibroblast autologous cell therapies - Fibrocell/Precigen Inc
Alternative Names: Genetically-modified autologous fibroblasts - Fibrocell Science/Precigen IncLatest Information Update: 28 Feb 2020
Price :
$50
*
At a glance
- Originator Fibrocell Science
- Developer Fibrocell Science; Precigen Inc
- Class Anti-inflammatories; Antipsoriatics; Cell therapies; Gene therapies
- Mechanism of Action Cell replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Arthritis; Ehlers-Danlos syndrome; Eosinophilia; Psoriasis
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for research development in Arthritis in USA (Parenteral)
- 03 Feb 2020 Intrexon Corporation is now called Precigen Inc
- 16 Dec 2019 Fibrocell Science has been acquired by Castle Creek Pharmaceuticals